ProKidney to present two posters at ASN Kidney Week 2025.
PorAinvest
lunes, 20 de octubre de 2025, 7:39 am ET1 min de lectura
PROK--
The first poster, titled "Renal Autologous Cell Therapy in Diabetes and CKD," will feature the late-breaking results of the Phase 2 REGEN-007 study. This study focuses on the use of renal autologous cell therapy to treat diabetes and CKD. The presentation will provide insights into the effectiveness and safety of the therapy, which is part of ProKidney's lead product candidate, Renal Autologous Cell Therapy (REACT), as described in a MarketScreener filing.
The second poster, "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," will delve into the inflammatory profile of the cell therapy candidate rilparencel. This poster aims to showcase the company's advancements in regenerative medicine and its potential to revolutionize the treatment of CKD, as noted in a StockTitan announcement.
ProKidney, founded in 2015, has been at the forefront of developing innovative cellular therapies for CKD. The company's lead product candidate, REACT, is designed to preserve kidney function in patients with CKD. ProKidney is currently conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT, with a focus on treating moderate to severe diabetic kidney disease (DKD), as reported in the MarketScreener filing.
The presentations at ASN Kidney Week 2025 will provide valuable updates on ProKidney's progress in the development of cellular therapeutics for CKD. The company aims to showcase its efforts in advancing the field of regenerative medicine and its potential to improve the lives of patients with CKD.
ProKidney Corp. will present two posters at ASN Kidney Week 2025, including a late-breaking poster on the Phase 2 REGEN-007 study results, focusing on renal autologous cell therapy in diabetes and chronic kidney disease. The company aims to showcase its efforts in developing cellular therapeutics for chronic kidney disease.
ProKidney Corp. (Nasdaq: PROK), a clinical-stage biotechnology company specializing in cell therapy platforms for chronic kidney diseases (CKD), has announced it will present two posters at the American Society of Nephrology (ASN) Kidney Week 2025. The event will be held from November 6 to 9, 2025, in Houston, Texas.The first poster, titled "Renal Autologous Cell Therapy in Diabetes and CKD," will feature the late-breaking results of the Phase 2 REGEN-007 study. This study focuses on the use of renal autologous cell therapy to treat diabetes and CKD. The presentation will provide insights into the effectiveness and safety of the therapy, which is part of ProKidney's lead product candidate, Renal Autologous Cell Therapy (REACT), as described in a MarketScreener filing.
The second poster, "Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel," will delve into the inflammatory profile of the cell therapy candidate rilparencel. This poster aims to showcase the company's advancements in regenerative medicine and its potential to revolutionize the treatment of CKD, as noted in a StockTitan announcement.
ProKidney, founded in 2015, has been at the forefront of developing innovative cellular therapies for CKD. The company's lead product candidate, REACT, is designed to preserve kidney function in patients with CKD. ProKidney is currently conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT, with a focus on treating moderate to severe diabetic kidney disease (DKD), as reported in the MarketScreener filing.
The presentations at ASN Kidney Week 2025 will provide valuable updates on ProKidney's progress in the development of cellular therapeutics for CKD. The company aims to showcase its efforts in advancing the field of regenerative medicine and its potential to improve the lives of patients with CKD.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios